Summary by Moomoo AI
EyePoint Pharmaceuticals, Inc. has appointed Reginald J. Sanders as a new Director to its board, effective January 8, 2025. This appointment is disclosed in a Form 3 filing with the United States Securities and Exchange Commission, indicating an initial statement of beneficial ownership of securities.The filing reveals that Sanders currently holds no beneficial ownership of any securities in the company, either in the form of non-derivative or derivative securities. This suggests Sanders is joining the board as an independent director without any pre-existing equity stake in EyePoint Pharmaceuticals.The Form 3 was signed by Ron Honig, acting as Attorney-in-Fact for Reginald J. Sanders, adhering to the regulatory requirements for reporting changes in insider ownership to the SEC.
